perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Evolution and neutralization escape of the SARS-CoV-2 BA.2.86 subvariant

3

Khadija Khan^{1,2}, Gila Lustig³, Kajal Reedoy¹, Zesuliwe Jule¹, Cornelius Römer^{4,5}, Farina Karim^{1,2}, Yashica Ganga¹, Mallory Bernstein¹, Zainab Baig¹, Boitshoko Mahlangu⁶, Anele Mnguni⁶, Ayanda Nzimande⁶, Nadine Stock⁶, Dikeledi Kekana⁶, Buhle Ntozini⁶, Cindy van Deventer⁷, Terry Marshall⁷, Nithendra Manickchund⁸, Bernadett I. Gosnell⁸, Richard J. Lessells^{3,9}, Quarraisha Abdool Karim^{3,10}, Salim S. Abdool Karim^{3,10}, Mahomed-Yunus S. Moosa⁸, Tulio de Oliveira^{3,9,11,12}, Anne von Gottberg^{6,13}, Nicole Wolter^{6,13}, Richard A Neher^{4,5}, Alox Sigal^{1,2,3}

10 Alex Sigal^{1,2,3}

¹Africa Health Research Institute, Durban, South Africa. ²School of Laboratory Medicine and Medical 11 Sciences, University of KwaZulu-Natal, Durban, South Africa. ³Centre for the AIDS Programme of 12 Research in South Africa, Durban, South Africa. ⁴Biozentrum, University of Basel, Basel, Switzerland. 13 ⁵Swiss Institute of Bioinformatics, Lausanne, Switzerland. ⁶Centre for Respiratory Diseases and 14 15 Meningitis, National Institute for Communicable Diseases, a division of the National Health Laboratory Service, Johannesburg, South Africa. ⁷Ampath Molecular Biology, Centurion, South Africa. ⁸Department 16 17 of Infectious Diseases, Nelson R. Mandela School of Clinical Medicine, University of KwaZulu-Natal, 18 Durban, South Africa. ⁹KwaZulu-Natal Research Innovation and Sequencing Platform, Durban, South 19 Africa. ¹⁰Department of Epidemiology, Mailman School of Public Health, Columbia University, New 20 York, USA. ¹¹Centre for Epidemic Response and Innovation, School of Data Science and Computational Thinking, Stellenbosch University, Stellenbosch, South Africa. ¹²Department of Global Health, 21 University of Washington, Seattle, USA. ¹³School of Pathology, University of the Witwatersrand, 22 23 Johannesburg, South Africa.

24

Omicron BA.2.86 subvariant differs from Omicron BA.2 as well as recently circulating 25 variants by over 30 mutations in the spike protein alone. Here we report on the first 26 isolation of the live BA.2.86 subvariant from a diagnostic swab collected in South Africa 27 which we tested for escape from neutralizing antibodies and viral replication properties 28 29 in cell culture. BA.2.86 did not have significantly more escape than Omicron XBB.1.5 from neutralizing immunity elicited by infection of Omicron subvariants ranging from 30 BA.1 to XBB, either by infection alone or as breakthrough infection in vaccinated 31 individuals. Neutralization escape was present relative to earlier strains: BA.2.86 32 showed extensive escape both relative to ancestral virus in sera from pre-Omicron 33 vaccinated individuals and relative to Omicron BA.1 in sera from Omicron BA.1 infected 34 35 individuals. We did not observe substantial differences in viral properties in cell culture relative to XBB.1.5. Both BA.2.86 and XBB.1.5 produced infection foci of similar size, 36 had similar cytopathic effect (both lower than ancestral SARS-CoV-2), and had similar 37 replication dynamics. We also investigated the relationship of BA.2.86 to BA.2 38 sequences and found that the closest were BA.2 samples from Southern Africa 39 40 circulating in early 2022. These observations suggest that BA.2.86 is more closely related to sequences from Southern Africa than other regions and so may have evolved 41 42 there, and that evolution led to escape from neutralizing antibodies similar in scale to recently circulating strains of SARS-CoV-2. 43

The Omicron subvariant BA.2.86 is derived from the BA.2 subvariant but has over 30 mutations in spike relative to both BA.2 and recently circulating subvariants such as XBB.1.5 (Fig.1A), making its emergence a major concern since many of the mutations are predicted to NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. confer escape from neutralizing antibodies (1). Levels of neutralizing antibodies have been

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

found to strongly correlate with protection from symptomatic infection with SARS-CoV-2 (2).
SARS-CoV-2 variant mutations occurring in the receptor binding domain and N terminal
domain of spike tend to reduce the ability of antibodies elicited by previous infection or
vaccination to neutralize SARS-CoV-2 (3-6), although protection from more severe disease
may be partly maintained by conserved T cell responses (7).

The Omicron BA.2.86 subvariant started to be identified by global genomic surveillance 53 54 samples collected from 24 July 2023 onwards, but because of the reduced rate of surveillance 55 the exact time when it started to spread is unclear. Likewise, it is unclear when and where it 56 arose. BA.2.86 shares the synonymous mutation C26681T and the spike substitution S939F 57 with BA.2 genomes sampled in South Africa in early 2022, while it lacks the mutation C9866T 58 that is present in the great majority of BA.2 sequences sampled outside of Southern Africa 59 (Fig 1B). Southern African sequences are also closely related to the putative ancestral sequence of BA.2.86. Of the 10 branches that emanate from the basal polytomy within 60 61 BA.2.86, 8 are dominated by samples from Southern Africa (Fig 1B). Most sequences from 62 the Northern Hemisphere fall into a second large polytomy designated as BA.2.86.1, 63 separated from the basal polytomy by two mutations. Available BA.2.86 sequences differ from their most recent common ancestor (MRCA) by 1-7 mutations. Most samples were collected 64 mid-August and have 3-5 mutations relative to the MRCA. SARS-CoV-2 accumulates about 65 66 15 mutations per year along acute transmission chains and we thus estimate that this subvariant started to spread about May 2023 (8). The estimate is corroborated by molecular 67 clock analysis with TreeTime, which suggests an emergence date in early May with an 68 uncertainty of about two months (Fig 1B). 69

The virus tested here is from a nasopharyngeal swab sample collected in Mpumalanga Province, South Africa on July 28, 2023 (Fig 1B, arrow). Sequence results were released on August 22, 2023 (GISAID accession GISAID accession EPI_ISL_18125249). Outgrowth to expand this virus was started on August 24, 2023, in the Vero-TMPRSS cell line, where two passages were performed (Materials and Methods). The sequence of the outgrown virus was deposited on GISAID (EPI_ISL_18226980) with no clear in-vitro sequence changes detected relative to the accepted Omicron BA.2.86 sequence.

77 Because the pressing concern is that BA.2.86 can escape current population immunity, we 78 compared neutralization of BA.2.86 to XBB.1.5 using sera from individuals who were vaccinated and had breakthrough infection with an Omicron subvariant (Fig 1C, see Table S1 79 for participant details), or infected with an Omicron subvariant only (Fig 1D, see Table S2 for 80 participant details). We found that there was no significant escape relative to XBB.1.5 in either 81 82 of these groups. The exceptions were two unvaccinated participants who were infected during the XBB dominant period who did show substantial BA.2.86 escape relative to XBB.1.5 (Fig. 83 84 1D and Table S2). However, it is difficult to determine if this is part of a pattern since we could 85 not enroll more unvaccinated XBB subvariant or later subvariant infected participants. Some 86 of the participants were people living with HIV (PLWH). In all except for one case HIV was suppressed with effective antiretroviral therapy. HIV status did not noticeably change the 87 88 similar neutralization of XBB.1.5 and BA.2.86 (Fig S1).

Next, we examined if this variant evolved escape to neutralizing immunity relative to earlier
SARS-CoV-2 strains. We checked neutralization of vaccinated individual sera collected preOmicron which we previously used to determine escape of the original Omicron BA.1
subvariant (3). Here, we found over 100-fold escape of BA.2.86 relative to ancestral SARSCoV-2, 5-fold greater than observed for BA.1 (Fig 1E). We also tested for escape relative to

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Omicron BA.1 in people infected with BA.1. Here we again found extensive escape, 14-fold relative to BA.1. However, XBB.1.5 showed a similar, 12-fold escape (Fig 1F).

96 We then investigated whether there were any differences in focus formation - the number of 97 cells infected by a single cell which formed an infected cell cluster. This is a measure of cell-98 to-cell spread of the virus (9). We also measured cytopathic effect and viral replication. We found that both BA.2.86 and XBB.1.5 made infection foci which were 5-fold and 4.5-fold 99 100 smaller in area relative to those made by ancestral SARS-CoV-2 at 20 hours post-infection (Fig 2A, quantitation in Fig 2B). The same viral inoculum led to considerable cytopathic (CPE) 101 effect by 72 hours in ancestral SARS-CoV-2 infected cells. Similar number of infection foci led 102 103 to substantially less CPE at the same timepoint in both BA.2.86 and XBB.1.5 infections (Fig. 104 2A). We also could not detect substantial differences in replication in cell culture between 105 BA.2.86 and XBB.1.5 (Fig 2C).

106 These results indicate that, although the Omicron BA.2.86 subvariant has evolved extensive escape from neutralizing antibodies, it is recognized by convalescent plasma to a similar 107 degree as the XBB.1.5 subvariant. This similarity in recognition might explain the 108 109 comparatively slow spread of the variant relative to the spread of BA.1 or BA.2 in 2021. These 110 observations are similar to data reported over the past week showing limited or no escape of 111 BA.2.86 relative to current circulating variants (10-12). Unlike the first study to report (11), we 112 did not obtain data consistent with lower cellular infectivity of BA.2.86 relative to XBB.1.5, although this may be because of the different cellular assays used. A limitation of our data is 113 114 that it is based on a single BA.2.86 isolate.

Our analysis suggests that BA.2.86 descends from viruses that circulated in early 2022 without any observed intermediates and only started to spread recently. There may be several explanations for the long period of evolution in the absence of population spread, including evolution in long-term SARS-CoV-2 infection during immunosuppression due to factors such as advanced HIV disease (13-15) as well as infection in an animal reservoir (15, 16).

120 While BA.2.86 may lead to new infections in the population, our data does not indicate that it 121 is very different than SARS-CoV-2 strains already in circulation.

122

123

124 Methods

125 Informed consent and ethical statement

126 Blood samples and nasopharyngeal swab for ancestral D614G SARS-CoV-2 isolation were 127 obtained after written informed consent from adults with PCR-confirmed SARS-CoV-2 128 infection who were enrolled in a prospective cohort study at the Africa Health Research Institute approved by the Biomedical Research Ethics Committee at the University of 129 KwaZulu-Natal (reference BREC/00001275/2020). The Omicron/BA.1 and BA.2.86 was 130 131 isolated from a residual swab sample with SARS-CoV-2 isolation from the sample approved by the University of the Witwatersrand Human Research Ethics Committee (HREC) (ref. 132 133 M210752). The sample to isolate XBB.1.5 was collected after written informed consent as part of the COVID-19 transmission and natural history in KwaZulu-Natal, South Africa: 134 135 Epidemiological Investigation to Guide Prevention and Clinical Care in the Centre for the AIDS Programme of Research in South Africa (CAPRISA) study and approved by the Biomedical 136

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

137 Research Ethics Committee at the University of KwaZulu–Natal (reference 138 BREC/00001195/2020, BREC/00003106/2021).

- 139
- 140

141 Reagent availability statement

142 Viral isolates are available upon reasonable request. Sequences of isolated SARS-CoV-2
143 used in this study have been deposited in GISAID with accession numbers as follows:

Virus	GISAID
D614G	EPI_ISL_602626.1
XBB.1.5	EPI_ISL_17506815
BA.2.86	EPI_ISL_18226980
BA.1	EPI_ISL_7886688

144

145 Sequences used in phylogenetic analysis: GISAID Identifier: EPI_SET_230907xn, doi:

146 10.55876/gis8.230907xn. All genome sequences and associated metadata in this dataset

147 are published in GISAID's EpiCoV database. To view the contributors of each individual

sequence with details such as accession number, Virus name, Collection date, Originating

Lab and Submitting Lab and the list of Authors, see 10.55876/gis8.230907xn

150 Data Snapshot: EPI_SET_230907xn is composed of 347 individual genome sequences. The

151 collection dates range from 2021-12-14 to 2023-08-30; Data were collected in 42 countries

152 and territories; All sequences in this dataset are compared relative to hCoV-

153 19/Wuhan/WIV04/2019 (WIV04), the official reference sequence employed by GISAID

154 (EPI_ISL_402124). For more information see at https://gisaid.org/WIV04.

155 <u>Whole-genome sequencing and genome assembly</u>

For the BA.2.86 swab sample, RNA was extracted on an automated Chemagic 360 156 157 instrument, using the CMG-1049 kit (Perkin Elmer, Hamburg, Germany). Libraries for whole genome sequencing were prepared using the Illumina COVIDseg Assay (Illumina Inc, San 158 159 Diego, CA) and version 4 SARS-CoV-2 primer pools. Pooled PCR products were fragmented 160 and tagged to adapter sequences. The adapter-tagged amplicons were purified and indexed 161 using sets 1-4 of PCR indexes (Illumina). Libraries were quantified using a Qubit 4.0 fluorometer (ThermoFisher Scientific, Oregon, USA) using the Qubit dsDNA High Sensitivity 162 assay according to the manufacturer's instructions. Fragment sizes were analyzed using the 163 164 TapeStation 4200 system (Agilent Technologies, Santa Clara, CA). Libraries were pooled and normalized to 4nM sample library with 2% PhiX spike-in. Libraries were loaded onto a 300-165 166 cycle NextSeg P2 Reagent Kit v2 and run on the Illumina NextSeg 1000/2000 instrument 167 (Illumina). Sequencing data was analyzed using Exatype v4.1.5 (Hyrax Biosciences, Cape Town, South Africa) with default parameters (10% minimum prevalence to report variants, 168 169 80% minimum prevalence to include a variant in consensus sequence). Nextclade (v2.14.1) 170 and Pangolin (v4.3, Pangolin-data v1.21) were used for clade and lineage assignments. 171 Additionally Nextclade was used for visualization of the sequences and the identification of

172 frameshifts. Unknown frameshifts were manually corrected using Aliview (v1.24).173 Outbreak.info was used to determine the prevalence of mutations.

For the BA.2.86 outgrowth sample, Oxford Nanopore sequencing was performed. RNA was 174 manually extracted from either 200uL input volume using either the MagMAX™ 175 Viral/Pathogen II Nucleic Acid Isolation Kit (Thermo Scientific) or from 140uL using the 176 QIAamp Viral RNA Kit (Qiagen) as per the manufacturer's protocols. All RNA extractions were 177 178 measured using Qubit fluorimeter kits (Thermo Scientific). The cDNA synthesis was performed 179 using LunaScript RT mastermix (New England BioLabs) followed by whole-genome multiplex PCR using the Midnight Primer pools v3 (EXP-MRT001, Oxford Nanopore) that produce 180 181 1,200-base-pair amplicons. The amplified products for each pool were combined and used to library preparation procedures using Oxford Nanopore Rapid Barcoding kit (SQK-RBK110.96, 182 183 Oxford Nanopore). The barcoded samples were pooled and cleaned-up using magnetic beads and loaded on an R9.4.1 flow cell for 8-hours sequencing on a MinION device. The raw data 184 was processed using Guppy basecaller and Guppy barcoder (Oxford Nanopore) for 185 186 basecalling and demultiplexing. The final consensus sequences were obtained using the Genome Detective v2.64. The lineage assignment was determined using Nextclade. 187

188 Phylogenetic analysis

We assembled a set of 280 BA.2 (Nextstrain clade 21L) sequences collected between 189 November 2021 and June 2022 from data deposited on GISAID (17). BA.2.86 sequences 190 191 were downloaded on September 7 2023 directly from GISAID. We excluded sequences with 192 reversion mutations relative to BA.2, sequences flagged as poor quality by Nextclade (18), or 193 sequences with less than 90% coverage of the reference. Sequences were pairwise aligned against Wuhan-Hu-1 using Nextclade. Terminals and gaps were masked as well as all 194 195 suspected artefactual reversions to reference in BA.2.86 sequences. A tree was built using 196 IQ-tree 2 (19) and postprocessed using a custom script to correct for incomplete merging of 197 branches in large polytomies.

A time tree was inferred using TreeTime (20) using a clock rate of 0.0005 per site and year [Neher 2022]. The rate of the long branch between BA.2 and BA.2.86 was set to be 2 times the rate of the rest of the tree in line with previous observation that evolution is 2-fold accelerated along many long branches leading to distinct clades [Neher (2022)]. This acceleration is consistent with the dramatic enrichment of amino acid substitutions in the spike protein along the long branch leading to BA.2.86.

The phylogenetic workflow is available at github.com/neherlab/BA286. The repository contains a specific list of sites (config/mask.tsv) that are masked in individual sequences.

- 206 An interactive version of the phylogenetic tree is available at
- 207 <u>https://nextstrain.org/groups/neherlab/ncov/BA.2.86</u>
- 208 <u>Cells</u>

209 The VeroE6 cells expressing TMPRSS2 and ACE2 (VeroE6-TMPRSS2), originally BEI 210 Resources, NR-54970 were used for virus expansion and all live virus assays excluding replication. The Vero-TMPRSS2 cell line was propagated in growth medium consisting of 211 Dulbecco's Modified Eagle Medium (DMEM) with 10% fetal bovine serum (Hyclone) containing 212 10mM of hydroxyethylpiperazine ethanesulfonic acid (HEPES), 1mM sodium pyruvate, 2mM 213 L-glutamine and 0.1mM nonessential amino acids (Sigma-Aldrich). The H1299-E3 (H1299-214 215 ACE2, clone E3) cell line used in the replication assay was derived from H1299 (CRL-5803) and propagated in growth medium consisting of complete Roswell Park Memorial Institute 216

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

(RPMI) 1640 with 10% fetal bovine serum containing 10mM of HEPES, 1mM sodium pyruvate,
 2mM L-glutamine and 0.1mM nonessential amino acids.

219

220

221 <u>Virus expansion</u>

222 All work with live virus was performed in Biosafety Level 3 containment using protocols for 223 SARS-CoV-2 approved by the Africa Health Research Institute Biosafety Committee. VeroE6-TMPRSS2 cells were seeded at 4.5×10^5 cells in a 6 well plate well and incubated for 18–20 224 hours pre-infection. After one Dulbecco's phosphate-buffered saline (DPBS) wash, the sub-225 confluent cell monolayer was inoculated with 500µL with universal transport medium which 226 contained the swab, diluted 1:2 with growth medium filtered through a 0.45µm and 0.22µm 227 228 filters. Cells were incubated for 2 hours. Wells were then filled with 3 mL complete growth medium. After 3 days of infection (completion of passage 1 (P1)), supernatant was collected, 229 cells were trypsinized, centrifuged at 300 rcf for 3 min and resuspended in 3mL growth 230 231 medium. All infected cells and supernatant were added to VeroE6-TMPRSS2 cells that had 232 been seeded at 1.5 x 10⁵ cells per mL, 20mL total, 18–20 hour earlier in a T75 flask for cell-233 to-cell infection. The coculture was incubated for 1 h and the flask was filled with 20mL of 234 complete growth medium and incubated for 3 days. The viral supernatant from this culture 235 (passage 2 (P2) stock) was used for experiments.

236 Live virus focus forming assay and neutralization assay

VeroE6-TMPRSS2 cells were plated in a 96-well plate (Corning) at 30,000 cells per well 1 day 237 238 pre-infection. Plasma was separated from EDTA-anticoagulated blood by centrifugation at 500 rcf for 10 min and stored at -80 °C. Aliguots of plasma samples were heat-inactivated at 56 °C 239 240 for 30 min and clarified by centrifugation at 10,000 rcf for 5 min. Virus stocks were used at approximately 50-100 focus-forming units per microwell and added to diluted plasma in 241 242 neutralization assays. Antibody-virus mixtures were incubated for 1 h at 37 °C, 5% CO₂. Cells 243 were infected with 100 µL of the virus–antibody mixtures for 1 h, then 100 µL of a 1X RPMI 244 1640 (Sigma-Aldrich, R6504), 1.5% carboxymethylcellulose (Sigma-Aldrich, C4888) overlay was added without removing the inoculum. Cells were fixed 20 h post-infection using 4% PFA 245 246 (Sigma-Aldrich) for 20 min. Foci were stained with a rabbit anti-spike monoclonal antibody 247 (BS-R2B12, GenScript A02058) at 0.5 µg/mL in a permeabilization buffer containing 0.1% 248 saponin (Sigma-Aldrich), 0.1% BSA (Sigma-Aldrich) and 0.05% Tween-20 (Sigma-Aldrich) in 249 PBS. Plates were incubated with primary antibody for 2 h at room temperature with shaking, 250 then washed with wash buffer containing 0.05% Tween-20 in PBS. Secondary goat anti-rabbit 251 HRP conjugated antibody (Abcam ab205718) was added at 1 µg/mL and incubated for 2 h at 252 room temperature with shaking. TrueBlue peroxidase substrate (SeraCare 5510-0030) was 253 then added at 50 µL per well and incubated for 20 min at room temperature. Plates were 254 imaged in an ImmunoSpot Ultra-V S6-02-6140 Analyzer ELISPOT instrument with BioSpot 255 Professional built-in image analysis (C.T.L) which was also used to guantify areas of individual 256 foci.

257 Plaque Assay

VeroE6-TMPRSS2 cells were plated in a 96-well plate (Corning) at 30,000 cells per well 1 day
pre-infection. Virus stocks were used at the focus-forming units per microwell shown in Figure
2 and added cells, incubated for 1 h at 37 °C, 5% CO2. Following incubation, 100µL of a 1X
RPMI 1640 (Sigma-Aldrich, R6504), 1.5% carboxymethylcellulose (Sigma-Aldrich, C4888)
overlay was added without removing the inoculum. Cells were fixed 72 hours post-infection

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

using 4% PFA (Sigma-Aldrich) for 20 min. The fixed cells were washed with distilled water and stained with 30 μL/well of a 0.5% crystal violet solution (Sigma-Aldrich, 61135).

265 Cycle threshold values for SARS-CoV-2 RNA copies

266 SARS-CoV-2 cycle threshold (Ct) quantification was performed from sample supernatant at 267 an accredited diagnostic laboratory (Molecular Diagnostic Services, Durban, South Africa). 268 Samples were extracted using a guanidine isothiocyanate/ magnetic bead based method with the NucliSense (Biomerieux) extractor of the KingFisher Flex 96 (Thermo Fisher). RT-gPCR 269 270 was performed using the Seegene Allplex 2019 nCoV assay with the Bio-Rad CFX96 realtime PCR instrument as per the kit instructions. RNase P is used as the internal housekeeping 271 gene to monitor extraction and assay efficiency. The kit targets the E, N and R genes of SAR 272 CoV-2. Run calls and interpretation is performed by the Seegene Viewer software. Fold-273 change was calculated as FC = 2^{((mean(Ct input) - Ct sample)} 274

275 Statistics and fitting

All statistics and fitting were performed using custom code in MATLAB v.2019b. Neutralization
 data were fit to:

278 $Tx=1/1+(D/ID_{50})$. (1)

Here Tx is the number of foci at plasma dilution D normalized to the number of foci in the absence of plasma on the same plate. ID_{50} is the plasma dilution giving 50% neutralization. FRNT₅₀ = 1/ID₅₀. Values of FRNT₅₀ <1 are set to 1 (undiluted), the lowest measurable value. We note that the most concentrated plasma dilution was 1:25 and therefore FRNT₅₀ < 25 were extrapolated.

284

285 <u>Acknowledgements</u>

286 This study was supported by the Bill and Melinda Gates award INV-018944, Wellcome Trust 287 Award 226137/Z/22/Z, University of Washington Arboviral Research Network (UWARN) Subaward #UWSC14272 and the South African Medical Research Council to AS. We thank 288 289 the originating and submitting labs of the SARS-CoV-2 sequences used in this study for timely 290 sharing of their data (EPI_SET_230907xn). We particularly thank Amos Adler and his team 291 and the Danish COVID-19 Genomics Consortium, whose surveillance efforts have led to the 292 detection of BA.2.86. We thank github user Silcn and Andrew Rambaut for discussions of 293 phylogenetic aspects and sequence quality.

294 Competing interest statement

- 295 The authors declare no competing interests.
- 296

297

298

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

299 References

300

- 301 1. Dadonaite B, Crawford KHD, Radford CE, Farrell AG, Yu TC, Hannon WW, et al. A pseudovirus 302 system enables deep mutational scanning of the full SARS-CoV-2 spike. Cell. 2023;186(6):1263-303 78.e20. 304 2. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing 305 antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. 306 Nature medicine. 2021:1-7. 307 Cele S, Jackson L, Khoury DS, Khan K, Moyo-Gwete T, Tegally H, et al. Omicron extensively 3. 308 but incompletely escapes Pfizer BNT162b2 neutralization. Nature. 2021. 309 4. Khan K, Karim F, Ganga Y, Bernstein M, Jule Z, Reedoy K, et al. Omicron BA.4/BA.5 escape 310 neutralizing immunity elicited by BA.1 infection. Nat Commun. 2022;13(1):4686. 311 5. McCallum M, De Marco A, Lempp FA, Tortorici MA, Pinto D, Walls AC, et al. N-terminal 312 domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. Cell. 2021;184(9):2332-47 313 e16. 314 6. Barnes CO, Jette CA, Abernathy ME, Dam KA, Esswein SR, Gristick HB, et al. SARS-CoV-2 315 neutralizing antibody structures inform therapeutic strategies. Nature. 2020;588(7839):682-7. 316 Keeton R, Tincho MB, Ngomti A, Baguma R, Benede N, Suzuki A, et al. T cell responses to 7. 317 SARS-CoV-2 spike cross-recognize Omicron. Nature. 2022. 318 Neher RA. Contributions of adaptation and purifying selection to SARS-CoV-2 evolution. 8. 319 Virus Evolution. 2022;8(2). 320 9. Meng B, Abdullahi A, Ferreira IATM, Goonawardane N, Saito A, Kimura I, et al. Altered 321 TMPRSS2 usage by SARS-CoV-2 Omicron impacts tropism and fusogenicity. Nature. 2022. 322 10. Sheward DJ, Yang Y, Westerberg M, Öling S, Muschiol S, Sato K, et al. Sensitivity of BA.2.86 323 to prevailing neutralising antibody responses. bioRxiv. 2023:2023.09.02.556033. 324 Yang S, Yu Y, Jian F, Song W, Yisimayi A, Chen X, et al. Antigenicity and infectivity 11. 325 characterization of SARS-CoV-2 BA.2.86. bioRxiv. 2023:2023.09.01.555815. 326 12. Lasrado N, Collier A-r, Hachmann N, Miller J, Rowe M, Schonberg E, et al. Neutralization 327 Escape by SARS-CoV-2 Omicron Subvariant BA.2.86. bioRxiv. 2023:2023.09.04.556272. 328 13. Karim F, Bernstein M, Jule Z, Lustig G, Upton J-L, Ganga Y, et al. Emergence of neutralizing 329 antibodies associates with clearance of SARS-CoV-2 during HIV-mediated immunosuppression. 330 medRxiv. 2023:2023.08.18.23293746. 331 14. Cele S, Karim F, Lustig G, San JE, Hermanus T, Tegally H, et al. SARS-CoV-2 prolonged 332 infection during advanced HIV disease evolves extensive immune escape. Cell Host & Microbe. 2022. 333 Peacock TP, Penrice-Randal R, Hiscox JA, Barclay WS. SARS-CoV-2 one year on: evidence for 15. 334 ongoing viral adaptation. The Journal of General Virology. 2021;102(4). 335 Hoffmann M, Zhang L, Krüger N, Graichen L, Kleine-Weber H, Hofmann-Winkler H, et al. 16. 336 SARS-CoV-2 mutations acquired in mink reduce antibody-mediated neutralization. Cell Rep. 337 2021;35(3):109017. 338 17. Shu Y, McCauley J. GISAID: Global initiative on sharing all influenza data - from vision to 339 reality. Euro Surveill. 2017;22(13). 340 18. Aksamentov I, Roemer C, Hodcroft EB, Neher RA. Nextclade: clade assignment, mutation 341 calling and quality control for viral genomes. Journal of open source software. 2021;6(67):3773. 342 Minh BQ, Schmidt HA, Chernomor O, Schrempf D, Woodhams MD, von Haeseler A, et al. IQ-19. 343 TREE 2: New Models and Efficient Methods for Phylogenetic Inference in the Genomic Era. Mol Biol 344 Evol. 2020;37(5):1530-4. 345 20. Sagulenko P, Puller V, Neher RA. TreeTime: Maximum-likelihood phylodynamic analysis. 346 Virus Evol. 2018;4(1):vex042.
- 347

medRxiv preprint doi: https://doi.org/10.1101/2023.09.08.23295250; this version posted September 8, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Figure Legends 348

Figure 1: BA.2.86 evolution and neutralization escape. (A) Changes relative to Omicron 349 XBB.1.5 and BA.2. (B) Phylogenetic analysis. BA.2.86 sequences form a distinct cluster 350 351 separated from BA.2 sequences circulating late 2021/early 2022 by a long branch labeled 352 BA.2.86. Outgrown sample marked by arrow. The BA.2.86 branch connects to samples with 353 the mutations C26681T and C24378T (Spike: S939F) but lacks C9866T present in most BA.2 sequences. (C) Neutralization of BA.2.86 live virus versus XBB.1.5 by sera from 354 vaccinated individuals with breakthrough BA.1/BA.4/BA.5/XBB family subvariant infection. 355 356 Numbers above columns are group geometric mean titer FRNT₅₀ and fold-change. (D) 357 BA.2.86 versus XBB.1.5 neutralization by sera from unvaccinated individuals infected with 358 Omicron BA.1/BA.4/BA.5/XBB family subvariants. (E) Neutralization of BA.2.86 versus 359 ancestral D614G and BA.1 viruses by sera from vaccinated individuals collected before 360 Omicron emergence. (F) Neutralization of BA.2.86 versus Omicron BA.1 by sera from vaccinated and unvaccinated BA.1 infected individuals. Significant p-values were 361 ****p<0.0001, **p=0.0042 by the Wilcoxon Rank Sum test. 362

Figure 2: Omicron BA.2.86 replication and spread in cell culture. (A) Foci formed by 363 364 ancestral D614G, XBB.1.5, and BA.2.86 at 20 hours post-infection on Vero-TMPRSS2 cells (rows 1, 3, 5) and cytopathic effect formed by the same viral inoculum on Vero-TMPRSS2 at 365 72 hours post-infection (rows 2, 4, 6). Rows 1 and 2 were infected with ancestral SARS-366 367 CoV-2, 3 and 4 with XBB.1.5, and 5 and 6 with BA.2.86. Foci number per well is indicated 368 above each well. Bar is 2mm. (B) Quantitation of focus area for D614G, XBB.1.5, and BA.2.86. Significant p-values were ****p<0.0001 by the Wilcoxon Rank Sum test. (C) Fold-369 370 change in SARS-CoV-2 viral copies as determined using qPCR cycle threshold over 4 days of infection in H1299-ACE2 cells. 371

372 Figure S1: Neutralization escape of Omicron BA.2.86 relative to XBB.1.5 by HIV status.

373 (A) Neutralization of XBB.1.5 and BA.2.86 in vaccinated individuals with breakthrough

Omicron variant infection. Y-axis is neutralization as FRNT₅₀ and numbers above each 374

column are geometric mean titer (GMT) FRNT₅₀ for the group. Sera from people living with 375

HIV (PLWH) are on the left panel and HIV negative participants on the right. (B) 376

- 377 Neutralization of XBB.1.5 and BA.2.86 in unvaccinated individuals infected with Omicron
- 378 subvariants.

379



Figure 1: BA.2.86 evolution and neutralization escape. (A) Changes relative to Omicron XBB.1.5 and BA.2. (B) Phylogenetic analysis. BA.2.86 sequences form a distinct cluster separated from BA.2 sequences circulating late 2021/early 2022 by a long branch labeled BA.2.86. Outgrown sample marked by arrow. The BA.2.86 branch connects to samples with the mutations C26681T and C24378T (Spike: S939F) but lacks C9866T present in most BA.2 sequences. (C) Neutralization of BA.2.86 live virus versus XBB.1.5 by sera from vaccinated individuals with breakthrough BA.1/BA.4/BA.5/XBB family subvariant infection. Numbers above columns are group geometric mean titer $FRNT_{50}$ and fold-change. (D) BA.2.86 versus XBB.1.5 neutralization by sera from unvaccinated individuals infected with Omicron BA.1/BA.4/BA.5/XBB family subvariants. (E) Neutralization of BA.2.86 versus ancestral D614G and BA.1 viruses by sera from vaccinated individuals collected before Omicron emergence. (F) Neutralization of BA.2.86 versus Omicron BA.1 by sera from vaccinated and unvaccinated BA.1 infected individuals. Significant p-values were ****p<0.0001, **p=0.0042 by the Wilcoxon Rank Sum test.



Figure 2: Omicron BA.2.86 replication and spread in cell culture. (A) Foci formed by ancestral D614G, XBB.1.5, and BA.2.86 at 20 hours post-infection on Vero-TMPRSS2 cells (rows 1, 3, 5) and cytopathic effect formed by the same viral inoculum on Vero-TMPRSS2 at 72 hours post-infection (rows 2, 4, 6). Rows 1 and 2 were infected with ancestral SARS-CoV-2, 3 and 4 with XBB.1.5, and 5 and 6 with BA.2.86. Foci number per well is indicated above each well. Bar is 2mm. (B) Quantitation of focus area for D614G, XBB.1.5, and BA.2.86. Significant p-values were ****p<0.0001 by the Wilcoxon Rank Sum test. (C) Fold-change in SARS-CoV-2 viral copies as determined using qPCR cycle threshold over 4 days of infection in H1299-ACE2 cells.



Figure S1: Neutralization escape of Omicron BA.2.86 relative to XBB.1.5 by HIV status. A) Neutralization of XBB.1.5 and BA.2.86 in vaccinated individuals with breakthrough Omicron variant infection. Y-axis is neutralization as $FRNT_{50}$ and numbers above each column are geometric mean titer (GMT) $FRNT_{50}$ for the group. Sera from people living with HIV (PLWH) are on the left panel and HIV negative participants on the right. (B) Neutralization of XBB.1.5 and BA.2.86 in unvaccinated individuals infected with Omicron subvariants.

medRxiv preprint doi: https://doi.org/10.1101/2023.09.08.23295250; this version posted September 8, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Table S1: Vaccinated with Omicron BTI participants

	Sex	Age range	Sample collected (date)	Infecting variant [#]	Infection (date)	Vacc type	Last Vacc (date)	Infection to sample (date)*	HIV status	BA.1 FRNT50	XBB.1.5 FRNT50	BA.2.86 FRNT50
1	Μ	50-59	Jan 22	BA.1	Dec 21	BNT162b2	Aug 21	17	+	1335.8	256.4	186.0
2	Μ	30-39	Dec 21	BA.1	Dec 21	Ad26.COV2.S	Mar 21	23	-	731.7	42.6	41.5
3	Μ	30-39	Dec 21	BA.1	Nov 21	Ad26.COV2.S	May 21	21	-	1282.7	17.0	12.5
4	F	50-59	Dec 21	BA.1	Dec 21	BNT162b2	Jul 21	23	+	756.3	62.7	24.0
5	F	30-39	Jan 22	BA.1	Dec 21	Ad26.COV2.S	Apr 21	22	+	899.2	177.5	168.5
6	F	60-69	Jan 22	BA.1	Dec 21	BNT162b2	Jul 21	24	-	1221.8	83.6	52.8
7	F	50-59	Jan 22	BA.1	Dec 21	Ad26.COV2.S	Jul 21	23	+	522.3	82.9	49.4
8	Μ	30-39	Dec 21	BA.1	Dec 21	BNT162b2	Jul 21	27	-	486.5	17.2	14.6
9	F	30-39	Jan 22	BA.1	Dec 21	Ad26.COV2.S	Aug 21	21	-	619.0	34.6	12.3
10	F	80-89	Jan 22	BA.1	Jan 22	BNT162b2	Jul 21	22	-	1210.8	468.8	169.7
11	Μ	60-69	Jan 22	BA.1	Dec 21	BNT162b2	Jul 21	24	-	264.5	84.1	70.0
12	F	40-49	May 22	BA.5	Apr 22	BNT162b2	Aug 21	34	+	N/A	46.8	49.1
13	Μ	40-49	May 22	BA.5	May 22	Ad26.COV2.S	Feb 21	29	-	N/A	188.0	190.2
14	Μ	50-59	Aug 22	BA.5	Jul 22	BNT162b2	Nov 21	29	-	N/A	342.5	269.3
15	F	70-79	May 22	BA.5	N/A	BNT162b2	Jul 21	N/A	-	N/A	75.7	156.0
16	Μ	70-79	May 22	BA.5	N/A	BNT162b2	Jul 21	N/A	-	N/A	1.4	5.1
17	F	40-49	Jul 22	BA.5	N/A	Ad26.COV2.S	Mar 21	N/A	-	N/A	24.1	47.1
18	F	30-39	Feb 23	BA.5	Jan 23	BNT162b2	Oct 21	35	+	N/A	11.1	7.6
19	F	30-39	Mar 23	BA.5	Feb 23	BNT162b2	Jan 22	29	+	N/A	168.2	245.7
20	Μ	30-39	Mar 23	BA.5	Feb 23	BNT162b2	Jun 21	30	-	N/A	233.7	50.2
21	Μ	40-49	Jun 22	BA.5	May 22	BNT162b2	Sep 21	36	+	N/A	799.2	413.8
22	F	20-29	May 23	XBB	N/A	Ad26.COV2.S	Mar 21	N/A	-	N/A	1126.8	764.3
23	F	30-39	May 23	XBB	Apr 23	BNT162b2	Jul 21	14	-	N/A	629.2	349.5
24	F	50-59	Jun 23	XBB	May 23	BNT162b2	Sep 21	29	-	N/A	924.3	628.6
25	F	60-69	May 23	XBB	May 23	BNT162b2	Jul 21	13	+	N/A	504.6	404.4
26	F	70-79	May 23	XBB	N/A	BNT162b2	Nov 21	N/A	-	N/A	3262.3	2175.3
27	Μ	40-49	Jun 23	XBB	N/A	Ad26.COV2.S	Nov 21	N/A	-	N/A	948.2	353.7
28	F	40-49	May 23	XBB	N/A	Ad26.COV2.S	May 21	N/A	+	N/A	113.2	110.1
29	М	70-79	Oct 22	XBB	Oct 22	BNT162b2	Aug 21	14	-	N/A	2522.4	1273.2

#Determined by infection date. *Infection date is by date of diagnostic swab.

medRxiv preprint doi: https://doi.org/10.1101/2023.09.08.23295250; this version posted September 8, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

. Table S2: Unvaccinated with Omicron infection participants

	Sex	Age range	Sample collected (date)	Infecting Variant [#]	Infection Date*	Infection to sample (date)	HIV status	BA.1 FRNT50	XBB.1.5 FRNT50	BA.2.86 FRNT50
1	F	30-39	Jan 22	BA.1	Dec 21	23	+	7963.06	187.34	207.40
2	F	20-29	Dec 21	BA.1	Dec 21	21	-	540.03	36.06	68.98
3	F	20-29	Dec 21	BA.1	Dec 21	21	-	345.02	45.90	54.60
4	F	50-59	Jan 22	BA.1	Dec 21	31	+	290.00	76.89	64.08
5	F	60-69	Jan 22	BA.1	Dec 21	17	-	826.48	34.08	66.15
6	F	50-59	Jan 22	BA.1	Dec 21	27	+	316.99	25.57	39.76
7	F	50-59	Jan 22	BA.1	Dec 21	21	-	1046.76	49.91	30.38
8	F	50-59	Jan 22	BA.1	Dec 21	31	+	2001.21	157.74	133.82
9	F	30-39	May 22	BA.5	Mar 22	78	+	N/A	17.9	24.6
10	М	40-49	Jun 22	BA.5	May 22	35	+	N/A	384.2	558.9
11	F	50-59	Aug 22	BA.5	Jul 22	30	-	N/A	30.5	18.3
12	М	60-69	Aug 22	BA.5	Jul 22	27	-	N/A	254.3	203.7
13	F	40-49	Feb 23	BA.5	Jan 23	33	-	N/A	275.5	134.0
14**	F	30-39	Mar 23	BA.5	Mar 23	17	+	N/A	2003.2	1769.6
15	М	50-59	May 23	XBB	N/A	N/A	-	N/A	10239.0	1735.9
16	М	60-69	Apr 23	XBB	Apr 23	28	-	N/A	955.9	39.2

#Determined by infection date. *Infection date is by date of diagnostic swab. **Viremic. HIV viral load = 2383 copies/mL.

medRxiv preprint doi: https://doi.org/10.1101/2023.09.08.23295250; this version posted September 8, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Table S3: BNT162b2 Vaccinated pre-Omicron participants

	Sex	Age range	Sample collected (date)	Last Vacc. (date)	Vacc. to sample (days)	HIV status	D614G FRNT50	BA.1 FRNT50	BA.2.86 FRNT50
1	F	40-49	Sep 21	Aug 21	32	+	942.3	10.9	9.6
2	F	40-49	Oct 21	Sep 21	34	+	16919.6	984.1	76.0
3	F	60-69	Oct 21	Aug 21	63	-	11788.5	621.0	68.1
4	М	40-49	Oct 21	Oct 21	18	+	9629.4	749.5	36.7
5	М	70-79	Aug 21	Jun 21	38	-	5025.0	137.8	35.6
6	F	60-69	Jul 21	Jul 21	11	-	301.1	16.0	9.9
7	М	70-79	Jul 21	Jul 21	11	-	720.2	45.3	8.8
8	М	30-39	Aug 21	Jul 21	15	+	893.5	44.2	9.7
9	F	70-79	Jul 21	Jul 21	10	-	300.5	24.2	17.3
10	F	30-39	Jul 21	Jul 21	11	+	2002.2	75.8	16.2
11	F	20-29	Nov 21	Oct 21	31	-	3625.0	234.5	13.3
12	М	20-29	Nov 21	Oct 21	30	-	2963.4	104.0	27.7
13	F	60-69	Aug 21	Jul 21	28	-	59258.6	1143.2	74.3
14	М	60-69	Aug 21	Jul 21	26	-	71412.3	2779.6	117.2
15	F	40-49	Nov 21	Oct 21	33	+	15276.3	1104.9	327.6
16	М	50-59	Oct 21	Sep 21	30	-	21376.2	759.2	72.7
17	F	50-59	Nov 21	Oct 21	13	-	2915.2	385.3	90.7
18	F	60-69	Nov 21	Nov 21	14	+	12699.9	174.2	117.7
19	F	30-39	Aug 21	Jul 21	34	+	258.6	4.6	5.4